Altimmune to Present at Two Upcoming Virtual Investor Conferences

Altimmune, a clinical-stage biopharmaceutical company (Nasdaq: ALT), announced its participation in two upcoming virtual investor conferences.

Rhea-AI Summary

Altimmune, a clinical-stage biopharmaceutical company (Nasdaq: ALT), announced its participation in two upcoming virtual investor conferences. The first is the H.C. Wainwright Hepatitis B Virus Conference on October 20, 2020, at 1:30 PM EDT, which will be webcast through the company's investor relations page. The second event is the B. Riley Securities Liver Disease Symposium on October 29, 2020. Altimmune specializes in intranasal vaccines and therapies for liver diseases, including COVID-19 and hepatitis B.

Argus Session date unavailable

+2.58% session move Open Argus

Details

News Market Reaction – ALT

The recorded move for ALT in the trading session of this news was +2.58%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

GAITHERSBURG, Md., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company advancing proprietary intranasal vaccines and peptide therapeutics for liver disease, today announced that management will present at the following upcoming virtual investor conferences:

• H.C. Wainwright Hepatitis B Virus (HBV) Virtual Conference
  Tuesday, October 20, 2020 – 1:30 pm EDT
  

• B. Riley Securities – Liver Disease Symposium
  Thursday, October 29, 2020
  

The H.C. Wainwright HBV presentation will be webcast and can be accessed by visiting the investor relations section of the company's website at www.altimmune.com under Events / Presentations.

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. The Company’s diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell). For more information on Altimmune, please visit www.altimmune.com.

Investor Contacts:

Stacey Jurchison	Ashley R. Robinson
Altimmune, Investor Relations	LifeSci Advisors, LLC
Phone: 410-474-8200	617-430-7577
sjurchison@altimmune.com	arr@lifesciadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the date of Altimmune's participation in the H.C. Wainwright conference?

Altimmune will participate in the H.C. Wainwright Hepatitis B Virus Virtual Conference on October 20, 2020.

When will Altimmune present at the B. Riley Securities Liver Disease Symposium?

Altimmune's presentation at the B. Riley Securities Liver Disease Symposium is scheduled for October 29, 2020.

How can I access the webcast of Altimmune's presentation?

The webcast of Altimmune's presentation at the H.C. Wainwright conference can be accessed via the investor relations section of their website.

What are the main products Altimmune is developing?

Altimmune is developing intranasal vaccines for COVID-19, anthrax, and influenza, along with therapies for liver diseases.

What is Altimmune's stock symbol?

Altimmune's stock symbol is ALT.